This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 979 entries already.
The Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn.<span style="mso-ansi-language:EN-US" lang="EN-US"> Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and […]
Ipsen SA and RNA splicing modifier specialist Skyhawk Therapeutics Inc have entered a US$1.8bn licencing option deal in rare neurological disorders.
French drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.
Waste based biosurfactants producer Amphistar BV has closed a €6m funding round led by the European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF).
Vaccine maker Sumagen Co. Ltd has launched a cGMP manufacturing partnership with French Naobios SAS for clinical testing of Sumagen’s inactivated HIV vaccine candidate.<br /> <br /><b><br /></b>
Finnish Solar Foods Oy has started microbial production of its protein powder Solein in Factory 01, Solar Foods’ first commercial-scale production facility in Vantaa, Finland.
German AdrenoMed AG has got FDA Fast Track designation for its targeted septic shock medicine enibarcimab that restores endothel integrity. <br /><br /><br /><br />
ALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.
Essential Pharma has acquired Renaissance Pharma Ltd to commercialise the company’s Phase II program Hu14.18K322A in pedriatric high-risk neuroblastoma.<br /><br />
Global health agency Unitaid has awarded French Medincell Corp (Jacou) an extension grant of up to US$ 6 million over three years to fund thesatety testing of its malaria vaccine […]